Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Kashihara

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 19, 2025
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort StudyManel Pladevall-Vila, Ryan Ziemiecki, Catherine B Johannes, et al.
Clinical and Experimental Nephrology|August 12, 2022
Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)Tomonori Kimura, Ryohei Yamamoto, Mitsuaki Yoshino, et al.
International Journal of Epidemiology|January 9, 2022
Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney diseaseJie Zheng, Yuemiao Zhang, Humaira Rasheed, et al.
Clinical and Experimental Nephrology|March 9, 2020
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|April 22, 2018
Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|June 21, 2020
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 19, 2025
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort StudyManel Pladevall-Vila, Ryan Ziemiecki, Catherine B Johannes, et al.
Clinical and Experimental Nephrology|August 12, 2022
Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)Tomonori Kimura, Ryohei Yamamoto, Mitsuaki Yoshino, et al.
International Journal of Epidemiology|January 9, 2022
Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney diseaseJie Zheng, Yuemiao Zhang, Humaira Rasheed, et al.
Clinical and Experimental Nephrology|March 9, 2020
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|April 22, 2018
Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|June 21, 2020
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, et al.
Pageof 21